How much does a box of genuine entrectinib targeted drug cost?

Entrectinib (Entrectinib), trade name Rozlytrek, is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI) of tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS 1) and anaplastic lymphoma kinase (ALK). In people with these types of cancer, treatment can be beneficial when other treatments are unavailable or don't work. The results currently available suggest that treatment with entrectinib can reduce tumor size and side effects are considered manageable.

It was approved for medical use in the United States in August 2019, in Australia in May 2020, in the European Union in July 2020, and in China in July 2022. Entrectinib and its active metabolite inhibit several pathways that contribute to cell survival and proliferation. This inhibition changes the balance in favor of apoptosis, thereby preventing cancer cell growth and shrinking tumors.

A capsule version of the original drug entrectinib has been launched in China. The drug is also covered by medical insurance, and patients who meet the indications can use medical insurance for reimbursement. Its common specifications include 100 mg with 30 capsules and 200 mg with 90 capsules, and the price is about more than 20,000 yuan per box. In comparison, the European version of the original drug marketed overseas is more expensive, and the price of 200mg*90 tablets may exceed more than 40,000 yuan (the price may change due to exchange rate fluctuations).

In addition, generic drugs of entrectinib are also sold overseas, and their ingredients are roughly the same as the original drug. For example, drugs of the same specification produced in Laos are priced between 1-6,000 yuan (the price may fluctuate due to exchange rates).